Validation of Patient-Reported Outcomes Measures for the Assessment of GERD [gastro-oesophageal reflux disease] Symptoms and Their Subsequent Impact on Patients With Partial Response to PPI [proton pump inhibitors] Treatment in a Two Part Multi-Center Phase IIa Study Including a Four Week Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Treatment Period.

Trial Profile

Validation of Patient-Reported Outcomes Measures for the Assessment of GERD [gastro-oesophageal reflux disease] Symptoms and Their Subsequent Impact on Patients With Partial Response to PPI [proton pump inhibitors] Treatment in a Two Part Multi-Center Phase IIa Study Including a Four Week Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Treatment Period.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2011

At a glance

  • Drugs Antacid compounds/simethicone; Lesogaberan
  • Indications Gastro-oesophageal reflux
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Jun 2011 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
    • 17 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Dec 2008 Planned end date changed from 1 Jan 2009 to 1 Feb 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top